VAX 161

Drug Profile

VAX 161

Alternative Names: Influenza A virus H5N1 vaccine – VaxInnate; VAX-161C; VAX161; VAX161B; VAX161B [STF2.HA5 H5N1]

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator VaxInnate
  • Class Antivirals; Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention, In volunteers) in USA (IM, Injection)
  • 01 Dec 2013 VaxInnate completes a phase I trial in Influenza-A virus H5N1 subtype (in volunteers, prevention) in USA (NCT01658800)
  • 30 Nov 2013 VaxInnate completes a phase I trial in Influenza-A virus H5N1 subtype (in volunteers, prevention) in USA (NCT01560793)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top